Plan B Mechanism Of Action At The Heart Of Panel Labeling Debate
This article was originally published in The Tan Sheet
Women who are considering using Barr Laboratories' Plan B (levonorgestrel .75 mg) should know the drug's mechanism of action at the point of purchase, according to FDA advisory committee panelists
You may also be interested in...
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
Women's Capital Corporation "is in discussions with a number of potential strategic marketers" to sell an OTC version of its Plan B emergency contraceptive pending approval of the firm's April 21 switch application
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC